Last updated on August 2020

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis


Brief description of study

To evaluate the long-term safety of Spesolimab in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials To evaluate the long-term efficacy of Spesolimab in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials

Clinical Study Identifier: NCT03648541

Find a site near you

Start Over

Guy's Hospital

London, United Kingdom
  Connect »

AdventHealth Orlando

Orlando, FL United States
  Connect »

Sagact, Pllc

San Antonio, TX United States
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Kangbuk Samsung Hospital

Seoul, Korea, Republic of
  Connect »

Severance Hospital

Seoul, Korea, Republic of
  Connect »

Barnsley Hospital

Barnsley, United Kingdom
  Connect »

Doncaster Royal Infirmary

Doncaster, United Kingdom
  Connect »

Whiston Hospital

Prescot, United Kingdom
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

Sameshima Hospital

Kagoshima, Kagoshima, Japan
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Ofuna Chuo Hospital

Kanagawa, Kamakura, Japan
  Connect »

Emory University

Atlanta, GA United States
  Connect »

Digestive Disease Specialists Inc

Oklahoma City, OK United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.